Solid Performance in the First Quarter of 2016 with Business EPS(1) up 5.3% at Constant Exchange Rates

Uutinen   •   Touko 02, 2016 12:41 EEST

Sanofi Chief Executive Officer, Olivier Brandicourt, commented: “I am pleased with the solid performance of the Group in the first quarter driven by Sanofi Genzyme, Sanofi Pasteur and Merial as well as our growth in Emerging Markets. At the same time, we have made significant progress with two major late-stage pipeline assets, dupilumab and sarilumab, highlighting the potential of our emerging immunology franchise. As we enter the second quarter, we remain focused on the execution of our strategic priorities and confirm our financial outlook of broadly stable Business EPS at CER for the full year.”